Aadi Bioscience Announces FDA Approval of its First Product FYARRO(TM) for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Stock Information for Aadi Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aadi Bioscience Inc.

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.